Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium

Résumé fourni par la source

BACKGROUND: Differences in cardiac sarcoidosis between racial groups remain understudied. Therefore, this study aims to explore race differences in patients with cardiac sarcoidosis. METHODS: We analyzed data from the Cardiac Sarcoidosis Consortium, an international registry including over 25 centers. The primary clinical outcome was a composite end point of all-cause mortality, left ventricular assist device implantation, heart transplantation, or implantable cardioverter defibrillator therapy. RESULTS: A total of 619 patients were included in the study (362 White, 193 Black, and 64 other races). Black patients were diagnosed with cardiac sarcoidosis at a younger age (50.5±11.8 versus 53.7±10.5 years old; P =0.010) compared with White patients. Left ventricular ejection fraction was significantly lower in Black patients (44.6±15.4 versus 48.3±14.0; P =0.008). In addition, extracardiac involvement in the lungs (80.3% versus 72.7%; P =0.046), skin (22.8% versus 12.4%; p =0.002), and eyes (13.5% versus 5.5%; P =0.001) was more prevalent in Black patients. Patients had significantly higher rates of hypertension (69.9% versus 50.6%; P <0.001), diabetes (37.8% versus 21.0%; P <0.001), smoking (40.9% versus 26.8%; P <0.001), chronic obstructive pulmonary disease or emphysema (15.5% versus 4.1%; P <0.001), and chronic kidney disease (25.9% versus 12.4%; P <0.001). The treatment patterns including glucocorticoid (71% versus 74.3%; P =0.4), glucocorticoid-sparing (53.4% versus 59.9%; P =0.14), and implantable cardioverter defibrillator or cardiac resynchronization implantation (75.6% versus 73.8%; P =0.63), were similar. No significant differences were found in the primary outcome (29.5% in Black versus 28.5% in White; P =0.79). Subgroup analysis of the primary outcome also revealed no significant differences in both the left ventricular ejection fraction >35% group (24.1% in Black versus 25.9% in White; P =0.72) and the left ventricular ejection fraction ≤35% group (51% versus 42.5%; P =0.35). CONCLUSIONS: Black patients with cardiac sarcoidosis exhibited significantly higher rates of lung, skin, and eye involvement and comorbidities, but had similar cardiac clinical outcomes and all-cause mortality compared with White patients. Nonetheless, ascertainment bias cannot be excluded.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.